



# 2019 中国国际药物信息大会 DIA CHINA Meeting

5月20-23日 会议、展览及交流互动 | 北京国际会议中心  
May 20-23, 2019 | Beijing International Convention Center

## CALL FOR ABSTRACTS

**Submission Deadline**  
**October 31th, 2018 | Beijing Time**

# Table of Contents

About DIA China 2019	3	<a href="#">↗</a>
2019 Theme Offerings	5	<a href="#">↗</a>
Call for Abstracts Theme Listing	6	<a href="#">↗</a>
Regulatory Science	6	<a href="#">↗</a>
Data and Data Standards	7	<a href="#">↗</a>
Clinical Trials, Operations and Quality Compliance	8	<a href="#">↗</a>
Patient Engagement	9	<a href="#">↗</a>
Preclinical Development and Early-Phase Clinical Research	10	<a href="#">↗</a>
Clinical Safety and Pharmacovigilance	11	<a href="#">↗</a>
CMC and Generic Drugs	12	<a href="#">↗</a>
Medical Affairs and Scientific Communication	13	<a href="#">↗</a>
Development of Biologics and Biosimilars	14	<a href="#">↗</a>
Statistics	15	<a href="#">↗</a>
Artificial Intelligence	16	<a href="#">↗</a>
Professional Development	17	<a href="#">↗</a>
General Submission Requirements	18	<a href="#">↗</a>
Frequently Asked Questions	19	<a href="#">↗</a>

## About the DIA China 2019 Annual Meeting

DIA China Annual Meeting is the largest, event in the life sciences industry designed to foster the international exchange of actionable insights to improve health globally through the advancement of lifesaving medicines and technologies in APAC region.. **The DIA China 2019 Global Annual Meeting (DIA China 2019) will bring together 2000+ pharmaceutical R&D professionals from different continents and regions, involved at all levels of the health care product development spectrum, to discuss recent and upcoming transformational changes for China's innovation and regulatory environments..** DIA China 2019 boasts more than 120 exhibiting companies, over 13+ themes, and more than 80 sessions.

DIA China 2019 provides you with a rare opportunity to build on what you already know in the development of new therapies and accelerate efforts to enhance health and well-being. Where else can you meet with people from around the world, share knowledge, experience cross-functional content with real-world application from top speakers in the industry, and network with peers to build new relationships across multiple disciplines?

## Abstract Tip!

Our Theme Leaders have highlighted priority topics within their educational themes to provide direction on content they would like to receive via the Call for Abstracts. **You may submit abstracts addressing priority topics and/or topics relevant to the DIA China 2019 theme descriptions.** Both priority topics and theme-specific topics will be reviewed and considered by the Annual Meeting Program Committee (AMPC).

### What is a Priority Topic?

The Program Committee has identified several priority topics they believe to be of significant value to the DIA China 2019 program.

### What is a Theme-Specific Topic?

Theme-specific topics are topics that support the overall purpose for the theme.

DIA is committed to including the voice of the patient at DIA 2019. DIA's Patient Partner initiative continues to ensure that the perspectives of patient communities are part of the discourse in all of our content formats. **We encourage patients and patient representatives to submit abstract proposals, not only into the Patient Engagement theme, but to all relevant themes.** The Program Committee will be looking for these during the abstract selection process.

**Submission Deadline - Wednesday, October 31**

## Types of Abstracts

There are three types of abstracts you can submit for DIA China 2019, including a session, presentation, and pre-conference workshop. Each abstract type is defined herein and has its own format and structure and cannot be altered. You may submit more than one abstract.



### SESSION

A 75 minute session concept delivered lecture-style from the podium. The abstract author is considered the session chair and will be responsible for the following:

- Adhering to the program development policies and guidelines
- Meeting program development timelines
- Recruiting no more than three speakers and ensuring good representation/diversity in the selection of speakers (no more than one participant from the same company is permitted)
- Communicating with speakers regarding their role in the session and reviewing presentation materials; PowerPoint presentations are required from each speaker
- Managing the session, including the facilitation of audience questions and answers from the podium

At the time of submitting a session abstract, please indicate at least one individual who will be invited to participate in the offering. Please do not extend an invitation until a formal response from DIA has been received.

*\*Helpful Hint! Plan your submission separately and in advance by using this [session abstract template](#). Read a [sample session abstract](#).*



### PRESENTATION

A 20-minute presentation abstract addressing a specific topic. If selected, this abstract will be combined with other abstracts within a session. The abstract author is considered the presenter (co-presenters are not allowed) and will be responsible for the following:

- Adhering to the program development policies and guidelines
- Meeting program development timelines
- Working with Chair and other presenters in creating a balanced session
- Preparing and delivering a PowerPoint presentation

*\*Helpful hint! Plan your submission separately and in advance by using this [presentation abstract template](#). Read a [sample presentation abstract](#).*



### PRE-CONFERENCE WORKSHOP

A pre-conference workshop is an interactive learning experience designed to provide a deeper-dive into a specific topic in a small group setting. Each pre-conference workshop will be either half day or full day, held on May 20, 2019 (the day before the start of DIA China 2019 May 21 – 23)

- A half-day pre-conference workshop consists of three hours and 30 minutes of instruction, and will have a program chair.
- A full-day pre-conference workshop consists of seven hours of instruction, and will have a program chair.

## DIA China 2019 Themes



Regulatory Science



Innovative Breakthrough  
in Therapy



Data and Data Standards



Clinical Trials, Operations and  
Quality Compliance



Patient Engagement



Preclinical Development and  
Early Phase Clinical Research



Clinical Safety and Pharmacovigilance



CMC & Generics Drugs



Medical Affairs and  
Scientific Communication



Development of Biologics & Biosimilars



Statistics



Artificial Intelligence



Professional Development



Hot Topics and Late Breaker

## Regulatory Science



This theme addresses global laws, regulations, guidelines, and guidances that govern prescription biopharmaceutical and device product development, approval, and maintenance. Representatives from CNDA, FDA, EMA, PMDA and Health Canada authorities, and other regulatory experts will provide global updates, insights, and discussion on current issues, opportunities, and challenges through interactive forums.

DIA recommends this theme and associated sessions to professionals involved in: regulatory affairs and strategy, regulatory operations, regulatory information management, regulatory agencies, government affairs, legal affairs and compliance, policy and intelligence, clinical research and operations, PV, HTA, project management, and service providers developing tools and resources for use by sponsors and CROs.

## Included Topic Areas

Regulatory affairs, regulatory policy, regulatory intelligence, regulatory strategy, regulatory operation best practices, regulatory science, eSubmissions, regulatory document management; regulation pertaining to study endpoints, product labeling, biosimilars, combination products, advanced therapies (e.g., regenerative medicine, tissue products, gene therapy), companion diagnostics, devices.

## Priority Topics

- 1. Novel global development strategies and approvals, including industry and regulator pilot projects and newly emerging precedence**
  - a. Real-world data/real world evidence
  - b. Patient-focused medical product development
  - c. Use of digital technologies in product development
  - d. Human factors studies and challenges in advancing drug delivery technologies
- 2. Global development and international harmonization/convergence**
  - a. Global development strategies and impact on clinical trial design and implementation (e.g., multi-regional clinical trial)
  - b. Updates on ICH, and other harmonization/convergence initiatives
  - c. Effect of emerging regulations on global registration strategies
  - d. Compare/contrast health authority approaches to regulatory interactions with industry

### 3. Regulatory Communications

- a. Opportunities for early engagement with regulators during medical product development
- b. Communications during drug shortages, cyber-security challenges, and emergencies,
- c. Communications with patients and healthcare providers
- d. Global labeling modernization efforts

## Data and Data Standards



This theme will address data from the perspectives of:

- Sources, standards, quality, handling, and regulatory requirements
- Current and emerging applications of data and technologies for capturing data direct from patients

The full spectrum of data and its uses to support biopharmaceutical development, approval, and post-marketing applications will be covered in this theme including: clinical (including eClinical from electronic health records, wearables, and other mobile apps), and real-world data from large data sets (including registries and national datasets, claims data, and prescription fulfillment).

DIA recommends this theme and associated sessions to professionals involved in: informatics (bio and medical), data standards and quality control (and regulatory standards implementation specialists), data quality, clinical data management, clinical trial design, clinical operations, eClinical (electronic health records), submissions and global submissions, health economics outcomes research, biostatistics, medical writing, real world evidence roles, epidemiology, post-market studies, regulatory affairs and operations, and statistics.

### Included Topic Areas

Informatics, bioinformatics, data standards and standardization, data management, data quality, data systems, data integration, compliance, bioethics, data security, data privacy, transparency, big data, data sources, real-world data/real world evidence (RWD/RWE), eClinical, mobile data, EHRs, information technology, information systems, operational best practices, exploratory data techniques, data integration from multiple disparate data sources, technology to support patient reported data and outcomes.

### Priority Topics

1. GDPR: impact on data management practices and processes
2. Updated standards, guidance, and regulations: impact on the data professional
  - a. ICH M4, ICH M8
3. Data integrity: measuring and monitoring best practices
4. Data integration: pros, cons – best practices for sharing clinical trial data
5. The evolution of CDM in the digital world: changing roles and responsibilities
6. EHR data/eSource, wearable health: opportunities and challenges in integration with clinical trials
7. Real World Evidence: data harmonization, standardization, quality, and regulatory considerations
8. Virtual trials: what are they, how do you deliver and what does it mean to the CDM
9. Advanced e-clinical technology for quality improvement and compliance
10. e-Clinical integration: Challenges & Practices

## Clinical Trials, Operations and Quality Compliance



This theme covers clinical research development, operations, as well a comprehensive view of the quality landscape across the preclinical, clinical, and pharmacovigilance domains.

Sessions explore current and innovative methods to: evaluate technology advances/systems to support clinical research programs and integrate cross-functional management, clinical utility, and endpoint development with the use of mobile/digital technology; optimizing clinical trial enrollment and reviewing technological advances in clinical research operations; endpoints; optimal clinical operations management structures in small, medium, and large companies; program challenges and solutions in global clinical and multi-regional clinical trials; advances in Sponsor/CRO collaborations; vendor oversight; and the evolving value of real-world data. Also includes key topics in GLP, GCP, and PV quality, providing knowledge and resources needed to implement pragmatic, proactive, and effective quality management.

DIA recommends this theme and associated sessions to professionals involved in: clinical operations, clinical research, safety and pharmacovigilance, project management, patient centricity, sponsor, CRO, and regulatory agency organizations interested or working in: research and development, clinical research, clinical, preclinical, or PV quality, clinical monitoring, regulatory affairs, regulatory operations, compliance, pharmacovigilance, quality control/quality assurance, and clinical quality management systems. Also, potentially: medical affairs, regulatory affairs, vendor management/ alliance management, data management, and quality assurance.

### Included Topic Areas

ICH E series guidelines, clinical quality management systems, quality risk management, quality culture, clinical quality-by-design, proactive quality, quality indicators, risk indicators, clinical quality metrics, data quality, data integrity governance/frameworks, GCP, GLP, audits, risk-based auditing, inspection management, CAPAs, compliance, compliance oversight, global oversight CPM, CROs, SMO.

### Priority Topics

1. **QSM in clinical trial practice , best practice and lesson learnt**
2. **Self-inspection and inspection in practice and benefits in quality assurance**
3. **Evolving best practices in risk management and compliance with ICH E6 R2 practice in China**
  - a. Risk analysis, threshold determinations, processes, systems, documentation
  - b. Root cause analysis and CAPA
  - c. Compliance in small to mid-sized companies: Quality Systems, SOPs, vendor oversight, and risk management
4. **Global Trials, partnerships, and cross-functional collaborations**
  - a. CRO partnerships – collaborations, management, oversight, KPIs
  - b. Managing complex vendor landscapes/logistics: labs, samples, IMP, enrollment
  - c. Optimizing country selection
  - d. Real time Quality Assessments
  - e. Clinical operations: collaboration with PV, QA, data management, and regulatory



## Patient Engagement



This theme addresses meaningful patient engagement in medical product development, from early product development, and approval, through maintenance phases. It focuses on important questions for all stakeholders, including:

- How do we meaningfully engage patients and incorporate their voices into decision-making throughout the medical product lifecycle?
- How do we become truly patient- (and people-) centric in our approach?
- How do we operationalize patient-centric approaches in our day-to-day work?
- How can we measure the effectiveness of our efforts, both for patient outcomes and to meet the needs of other stakeholders such as industry and regulatory decision-makers?
- What have we learned that can be used to drive more meaningful patient engagement?
- How do stakeholders best work together to leverage their collective power and expertise to promote meaningful involvement of patients?

DIA recommends this theme and associated sessions to professionals involved in: patient affairs, patient advocacy, patient groups, patient support services, medical affairs (including CMOs and MSLs), clinical trial design and optimization, clinical research and operations, regulatory affairs, regulatory agency, corporate and government affairs, safety and pharmacovigilance, outcomes research, epidemiology, and Health Technology Assessment.

### Included Topic Areas

Meaningful patient engagement (PE), patient-centered drug development, patient centricity, fostering patient-centric culture, PE approaches, best practices for PE, building collaborative relationships with patients and patient groups, engaging with diverse patient populations, partnering with patients, science of PE, operationalizing PE, PE metrics, PE tools and resources, patient advocacy, lessons learned in PE, PE outcomes.

### Priority Topics

- 1. Patient engagement opportunities, challenges, and experiences in preparing for launch and post-launch**
  - a. Health Technology Assessment
  - b. How and when to partner with Commercial and Market Access
  - c. Patient programs, product-agnostic, and product-specific education
  - d. Regulatory and compliance considerations for regional launches
- 2. Impact of patient engagement on the biopharmaceutical industry's business and organization**
  - a. Developing and implementing organizational structures
  - b. Identifying and partnering with key internal stakeholders
  - c. Understanding and measuring impact of engagement on both the business and patients
- 3. Development, collection, utility, and impact of patient experience data**
  - a. Novel partnerships to generate long-term real world evidence
  - b. Measuring and communicating benefit-risk
  - c. Role of caregivers
  - d. Regulatory implications and experiences
- 4. Developing, executing, and evaluating meaningful collaborations between patients and industry across the entire therapeutic lifecycle**
  - a. Examples of various levels of collaborations throughout research, development, and commercial
- 5. Global implications, challenges, and ideas for patient advocacy and patient engagement**
  - a. Results and outcomes for patient communities
  - b. Evaluation (company and patient community perspectives)
  - c. Where do we go next?
  - d. Regional similarities and differences (including more than North America and Europe)
  - e. How to measure global impact
  - f. Multi-stakeholder collaborations
  - g. Regulatory considerations
- 6. Patient engagement and involvement in clinical trial development, execution, recruitment, enrollment, and retention**
- 7. Opportunities and challenges in the digital age of patient engagement**
  - a. Who can and can't engage with patients?
  - b. Remote sites and home healthcare
  - c. Role of CROs in patient engagement
  - d. Implications for the breadth/spectrum of disease populations
  - e. Handheld devices
  - f. Automation
  - g. Artificial intelligence
  - h. Implications for organization of patient communities

## Preclinical Development and Early-Phase Clinical Research



Preclinical and early-phase clinical research provide initial safety, tolerability, and efficacy data for new drugs. This theme focuses on topics ranging from early-stage compound selection, PK, and safety considerations for both drugs and biologics, as well as dosing strategies to data integrity for proper downstream decision-making.

DIA recommends this theme and associated sessions to professionals involved in: pharmacology and toxicology, nonclinical safety testing, clinical research, clinical operations, safety and pharmacovigilance, project management, patient centricity, and statistics; formulation science, pharmacokinetics/pharmacodynamics, epidemiology, toxicology, and regulatory affairs.

### Included Topic Areas

Personalized medicine; gene editing; clinical trial data disclosure; collaborations; bioethics; compliance; stem cells, regenerative therapies, gene therapies, etc.; ICH (S), study endpoints; integration of the 'patient's voice' early in preclinical development to define/refine the patient population and clinical endpoints; challenges in rare and common diseases.

### Priority Topics

1. Cellular immunotherapies for oncology: preclinical challenges and monitoring clinical toxicity
2. Novel CNS therapies and challenges in developing products for cognitive disorders
3. Accelerating rare disease product development: partnering with rare disease consortia during early development
4. Botanical products – Navigating the regulatory jungle
5. The virtual drug development model: minimizing overhead and maximizing chances for Phase 1 success
6. Tissue engineered and regenerative medicine products: preclinical and early clinical considerations
  - a. 3-D Printing of tissues and organs
  - b. Use and safety considerations for human stem cells
7. RNA-based therapies: CMC, nonclinical, and clinical challenges with a novel product class
8. Leveraging artificial intelligence in early stage development
9. Vaccine development for emerging viral diseases
10. Challenges in vaccine development for serious epidemic diseases in remote locations
11. The growing use of nucleic acid-based vaccines
12. Emerging genome editing technologies
13. Impact of New CNDA guidance for gene therapies
14. Drug development for ocular diseases: new therapies, regulations and patient perspectives

## Clinical Safety and Pharmacovigilance



This theme provides an overview of the global regulatory environment in the field of clinical safety and pharmacovigilance for medical products (biopharmaceutical products and medical devices), with a focus on pragmatic approaches to protecting patient safety and incorporating the patient voice into the complex and evolving pharmacovigilance ecosystem. Forward-thinking sessions address the application of new technologies and methods to streamline pharmacovigilance systems and processes to enhance protection of patient safety as products become more complex, new data sources drive new analytical techniques, regulatory requirements become more detailed, and medical product development becomes more global.

DIA recommends this theme and associated sessions to professionals involved in: drug safety/pharmacovigilance, medical product safety risk assessment, pharmacoepidemiology (including real world evidence generation), post-market studies (including Large Simple Safety Studies and pragmatic safety studies), statistics, benefit-risk assessment and management, benefit-risk communication (including professional and consumer medical product safety labeling), regulatory affairs, clinical research (including clinical trial design), medical affairs, and health outcomes.

### Included Topic Areas

New initiatives, and emerging regulatory requirements and expectations regarding drug safety-related policies, processes and best practices, and quality metrics, especially those relating to patient engagement; data privacy; Good Pharmacovigilance Practices (GVPs), including insights into revised modules; pre- and post-market safety; expansion of ICH “E2” guidelines to developing markets; benefit-risk assessment and management; epidemiologic studies and impact on labeling; safety considerations for combination products, medical devices, generic products (including biosimilars), and advanced therapies; companion diagnostics; pharmacovigilance audits/inspections; use of digital technology for risk identification, minimization, and communication; patient-centric labeling and risk minimization methods; application of artificial intelligence to pharmacovigilance; generating meaningful insights on medical product safety from social media and other new data sources; optimizing the global pharmacovigilance foot print (including local safety offices and partners); and considerations for signal detection and management across the product lifecycle.

### Priority Topics

- 1. What’s new in PV regulation and guidance?**
  - a. Incorporating the patient voice in the benefit-risk management process
  - b. General data protection regulation and PV
  - c. Combination products
  - d. GVP V and globalization of RMPs
- 2. PV audits/inspections**
  - a. New hot spots
- 3. The science of safety analytics**
  - a. Practical application of AI
- 4. The evolving world of PV data**
  - a. Real World Evidence and labeling
  - b. Impact of digital/wearable technology
- 5. Safety management planning**
  - a. Pre- and post-market continuity
- 6. Pragmatic approaches to globalization of PV**
  - a. Adoption of tier 2 ICH E2 guidelines
  - b. The “responsible” person

## CMC & Generic Drug



The CMC and Generic Drug Theme provides a comprehensive view of risk-based approaches across the product lifecycle. The theme scope spans from the scientific understanding gained through product and process development to lifecycle expectations for Global Regulatory CMC submissions, CGMP, and Generic Medicines. In this session, we will discuss what means high quality of generic drug from multiple angles; and why innovation is such important to R&D of generics as well as registration of generic drug. Sessions will also address the increasing regulatory complexity of development and manufacturing for worldwide markets, accelerated development timelines, new technologies, emerging regulations, and increased scrutiny of manufacturing operations and data.

### Included Topic Areas

CMC expectations for dossiers, quality management system expectations, new technologies, patient-centered quality risk management of products, and ICH quality related guidelines (Q & M topics).

### Priority Topics

1. New technologies
2. Update on ICH Q&M topics
3. Recent CMC changes in China
4. Interface between CMC assessment and inspection
5. Comparability for complex generic and biotech products
6. Challenges and opportunities in product quality: lifecycle management
7. cGMPs for combination products
8. Development and manufacturing challenges for advanced therapies medicinal products
9. Efficient preparation of global CMC dossiers

## Medical Affairs and Scientific Communication



This theme will share insights from medical affairs professionals and medical writers across the globe. Sessions within the theme will address necessary skills and best practices for working cross-functionally and compliantly within medical affairs, medical information, and scientific communication.

DIA recommends this theme and associated sessions to professionals involved in medical or regulatory scientific writing, medical communications, and medical information. Medical science liaisons are also a key audience.

### Included Topic Areas

Medical information; medical science liaison; medical writing; medical affairs roles throughout product lifecycle, stakeholder management, advisory boards, compliance.

### Priority Topics

1. The value of medical affairs across the lifecycle of the product
2. Global medical information perspectives from outside the United States
3. Topic-based authoring to support accelerated CTD submissions
4. Applying HEOR, real world evidence, and outcomes partnerships across medical affairs to meet HCP needs
5. Evolution of medical information response delivery channels
6. Maximizing medical affairs congress presence
7. Statistics for nonstatisticians
8. GDPR impact in clinical development, medical affairs, and medical information
9. Structured authoring in clinical development
10. Identifying key messages: protocol to publication
11. Clinical transparency and disclosure
12. Collaborating with patient advocacy groups in the orphan product space
13. Communicating study results to patients and patient advocacy groups
14. Medical Affairs roles for the future
15. Where do medical affairs' professionals gather and gain their role expertise?

### Development of Biologics and Biosimilars



The Development of Biologics and Biosimilars Theme provides the goal for either biologics or biosimilars. Sessions will share from regulatory perspective and industrial perspective, elaborate clinical design for biologics and biolimiars, as well the development and regulatory considerations of cell therapy.

The theme is recommended for regulatory affairs, manufacturing, quality assurance, and quality control professionals involved in: drug development and/or manufacturing for small molecule drugs, biologics, and biosimilars.

#### Priority Topics

1. The relevant laws and regulations for biosimilars
2. CNDA guidelines for the evaluation of biosimilar
3. Regulatory Expectation on the Clinical Design of Biosimilar
4. Innovative Biologics Process Development
5. Global cellular and gene therapy product regulations

## Statistics



This theme will focus on topics of theoretical and practical interest to statisticians and clinical trialists who work with medical products, including pharmaceuticals, biologics and biosimilars, combination products and devices, and generics throughout their lifecycle. Sessions will explore current statistical thinking which informs policy, regulation, development, review, and lifecycle management of medical products in the context of the current scientific and regulatory environments.

DIA recommends this theme to professionals involved in or seeking to advance their skills in biostatistics, including: biostatisticians, statistical programmers, clinical pharmacologists, health economists, epidemiologists, regulatory scientists, physicians, project leaders, and other clinical development practitioners.

### Included Topic Areas

Statistics, biostatistics, Bayesian statistics, novel statistical tools, data standards, analysis and analysis sets, data interpretation, data visualization, trial planning and design, adaptive designs, innovative designs, model-informed drug development, data monitoring committees, precision medicine and subpopulation analysis, biomarkers, multi-regional clinical trials, endpoint assessment, real world evidence, pragmatic trials, use of historical control, pediatric/rare disease drug development.

### Priority Topics

- 1. Raise your clinical research game with basic statistical knowledge**
  - a. Randomization, blinding, analysis populations
  - b. T-test, ANOVA, ANCOVA, Chi-square, Fishers, time-to-event/Kaplan-Meier
- 2. Data visualizations are coming: Are you ready?**
  - a. Static and dynamic
  - b. Safety and benefit-risk applications
- 3. Rare diseases**
- 4. Pediatric drug development**
- 5. Complex Innovative Designs/Model-Informed Drug Development**
- 6. Using real world evidence for regulatory decision-making**
- 7. Surrogate endpoints and biomarkers**
- 8. Innovative advances with a statistical twist**
  - a. Bayesian applications, ie. informative priors
  - b. Historical information
  - c. Artificial intelligence
  - d. Machine learning
  - e. Clinical analysis standards
- 9. Important considerations in clinical trials**
  - a. Multi-regional clinical trials (ICH E17)
  - b. Multiplicity
  - c. Missing data
  - d. Preparing for regulatory meetings, including creating questions/briefing documents
  - e. Use of statistics to inform decision-making
- 10. Getting the questions right (ICH E9 R1)**
  - a. Estimands
- 11. Patient-focused drug development**
- 12. How to collaborate effectively as a statistician**

### Artificial Intelligence



Cloud computing, big data, artificial intelligence, etc. are words of familiarity to us. People realize that the information age has entered a new chapter. Nowadays, the continuous development of intelligent information technology allows it for more and more extensive application. Also, machine learning is of great potential in increasing return for the whole medical industry, including mobile health, drug discovery and pharmaceutical analysis, treatment optimization, patient monitoring, and more. With the integration of artificial intelligence and machine learning, the objective of significant risk reduction will possibly be achieved, saving cost and increasing the efficiency of global medical information sharing. Thus, it indicates that a new intelligentized age of medical science has already begun.

#### Priority Topics

1. **Practical application of AI**
  - a. AI Practice in Regulatory Affairs
  - b. AI's Innovation in Clinical Trials
  - c. AI practice in PV
2. **Applications of blockchain, artificial intelligence, automation**
3. **Utilization and impact of AI and machine learning**
4. **Artificial intelligence in early stage development**



## Professional Development



The Professional Education and Development theme focuses its content on topics that improve and support ongoing personal growth for career and team success. This broad category includes: interpersonal skills, soft skills, leadership, goal-setting, life-long learning, career transitions (career growth, lateral career transitions, and entrepreneurship), social media/new media, and self-awareness to assess strengths and gaps.

### Included Topic Areas

Networking, improving productivity and self-productivity, interpersonal relationships, diversity, hiring, leadership, technology, making a lasting impression, running remote meetings and workplace dynamics.

### Priority Topics

1. **Networking:** hands-on networking, networking for people who hate networking, networking by personality profile, networking at conferences
2. **Workplace dynamics:** broadcasting happiness, creating a more positive workplace, strategies for more productive workspaces
3. **Interpersonal relationships:** co-worker interactions, feedback/review and critique, generational interaction and synergizing, communication styles, Myers Briggs/DISC/DOPE
4. **Benefits of diversity:** improved project performance with more voices, unique problem-solving, how diversity (age/gender/career background/LGBTQ/race/ethnicity) amplifies a workplace
5. **Diversity leadership in healthcare:** What does leadership look like for diverse groups (new-to-career, millennials, women in healthcare, people of color, etc.)?, challenges of leadership for diverse groups, workplace perceptions for diverse groups
6. **Hiring based on skillsets,** creative hiring strategies, cross-career/cross-functional strengths, asking good questions to hire talent, maximizing resume keywords and buzz words
7. **Leadership:** courageous leadership, service leadership, team dynamics, workplace culture
8. **Career transitions:** career growth/lateral career transitions/entrepreneurship, building a consulting practice (legal, financial, business development, marketing), work-life balance
9. **Best practices in new technology:** LinkedIn, apps for productivity, social media, remote meetings

## Abstract Submission Requirements

Please read the following instructions carefully; incorrect or incomplete abstracts will not be considered.

1. All abstracts must be submitted online to [DIAhome.org/Abstract](http://DIAhome.org/Abstract). The deadline for abstract submissions is **Wednesday, October 31, 11:59 PM Beijing Time**. This deadline will not be extended.
2. Submitted abstracts must not overtly endorse or recommend a specific product or service.
3. Proposed abstract title must reflect the abstract content accurately and concisely.
4. Co-presenters will not be allowed.

## Notification Date

Notification Timeline:

- Session and Pre-conference Workshop: Early Jan., 2019
- Presentation: End of Jan., 2019

Please note that DIA China and the DIA China 2019 Program Committee have the right to request authors to revise abstracts. Potential revisions include direction of topic, blending with another submission, or revising the proposed level of difficulty.

## Abstract Submission Tips and Tricks

- Do not wait until the last day to submit an abstract. There is usually very high traffic on the website and you want to avoid the risk of any technical difficulties.
- Do not use the “back” button during the submission process.
- Be certain to click “Submit” at the end of the process for a confirmation of receipt. If you do not get confirmation of receipt, DIA did not receive your abstract.

Questions? Contact DIA China at [China@DIAglobal.org](mailto:China@DIAglobal.org)

# Frequently Asked Questions

The following are helpful hints and frequently asked questions regarding abstract submissions for DIA China 2019.

**Q:** What constitutes a quality abstract?

**A:** Information provided in the “Abstract Details” section should include specific details or data to support your abstract submission:

- Unbiased content that does not promote a product, service, or organization; abstracts deemed to be promotional will be excluded from consideration
- Innovative and cutting edge information, or new developments related to the topic
- Real-world applications, such as case studies or demonstrations
- A global perspective
- A session or presentation title that is compelling and attractive to potential attendees
- Content that is cross-functional and interdisciplinary, if possible/appropriate
- A clear target audience with clear learning objectives

**Q:** May an author submit more than one abstract?

**A:** Authors may submit multiple abstracts. *Do not submit the same abstract more than once.*

**Q:** What information is required from the author?

**A:**

- Full contact information
- Participant disclosure information and speaker authorization for use of presentation materials, which allows DIA to distribute your presentation to registrants of the Annual Meeting

**Q:** Can there be more than one author name?

**A:** Only one author name may be submitted.

**Q:** May I include or recommend an additional speaker name for the topic in which I am interested?

**A:** You may recommend an additional speaker(s) for a session, forum, or workshop only.

**Q:** Do I have to use the [DIA website](#) to submit the abstract?

**A:** Yes. Only abstracts submitted via the DIA website will be considered for inclusion in the program. You are encouraged to prepare your abstract in a separate document prior to submitting on our website. Abstract information should then be copied and pasted from the prepared document as plain text.

**Q:** Are there abstract templates or samples available?

**A:** Yes, there is a sample abstract as well as a form that you may use to prepare your abstract in advance.

[Session abstract template](#)

[Presentation abstract template](#)

[Pre-conference workshop abstract template](#)

**Q:** May someone submit the abstract on my behalf?

**A:** Yes, for sessions, forums, and workshops, a submitter will have the option to complete author information even if they will not be the designee onsite in San Diego, CA.

**Q:** When will I be notified if my abstract has been accepted?

**A:** Authors will be notified the week of Jan. 1st, 2019 for session and pre-conference workshop; the week of Jan. 28th, 2019 for presentation.